Post by thekindaguyiyam on Apr 5, 2014 18:17:37 GMT -5
"This Week in Biotech: Data Disappointments Come in Threes"... diabetes medication, Afrezza, looked iffy at best. Following the release of the Food and Drug Administration's panel meeting briefing documents shortly before ... MannKind's wild ride
It was a wild week for clinical-stage biopharmaceutical company MannKind (NASDAQ: MNKD ) , which plunged by double digits on Monday after it appeared that an approval for its inhaled diabetes medication, Afrezza, looked iffy at best. Following the release of the Food and Drug Administration's panel meeting briefing documents shortly before its meeting with MannKind, investors swarmed the lukewarm excitement surrounding Afrezza.
That pessimism failed to last, though, with the FDA panel voting overwhelmingly -- 13-to-1 for type 1 diabetes and 14-0 for type 2 diabetes -- in favor of recommending Afrezza to be approved for glycemic control of both types of diabetes. Although this doesn't guarantee an approval by the FDA, it certainly makes a strong case for approval come its April 15 PDUFA decision date. I'd still remind investors that MannKind has yet to partner up, so until it does so, and until the FDA's decision is out, it might be best to wait patiently on the sidelines.
www.fool.com/investing/general/2014/04/05/this-week-in-biotech-data-disappointments-come-in.aspx
more of the same high quality journalism that we are use to from them.